The Pharmacist Everyone Depends On, But No One Designs Around

By Jamelia R. Hand MHS CASC CODP I

Nick ran the outpatient pharmacy at Jackson Park Hospital in a way that never felt transactional. Patients would walk up to the counter with a prescription, but what they were really bringing with them was a story. Some were doing well and just needed a refill. Others were barely holding it together and trying to make it through another day without using. Nick knew the difference without needing a chart in front of him. He paid attention to patterns, to tone, to timing. He knew who came early, who came late, who missed doses, and who might not come back at all.

Providers trusted him because he saw what they could not always see between visits. Patients trusted him because he treated them like people, not problems. And when something felt off, he did not just fill the prescription and move on. He picked up the phone, asked questions, and helped close gaps that could have easily turned into relapse or worse.

That kind of pharmacist is not rare. But that kind of pharmacist is rarely built into the way we design outpatient treatment for opioid use disorder.

Seeing the Community from the Counter

Pharmacists have a vantage point that most of the healthcare system does not. They are one of the few professionals who consistently interact with patients across different stages of stability, and they do so in real time, without an appointment, without a referral, and without the layers that often delay care.

Over time, they begin to recognize patterns that are not always visible in clinical settings. They see which neighborhoods struggle with consistent access to medication. They notice when prescriptions from certain providers are filled regularly and when others are not. They can tell when a patient’s routine shifts in a way that might signal instability. None of this shows up immediately in reports or dashboards, but it is happening every day at the counter.

From a consultant perspective, this is one of the most underutilized sources of insight in outpatient treatment. We talk a lot about data, but we do not always acknowledge where some of the most valuable information actually lives.

Stephanie and the Standard She Set

I also think about Stephanie, who led the Chicago Pharmacists Association with a level of commitment that was hard to match. She approached her work with a clear understanding that pharmacists are not separate from the care team. They are part of it, whether systems formally recognize that or not.

What stood out about Stephanie was her focus on education and alignment. She made sure pharmacists had the knowledge they needed to support patients with opioid use disorder, and she worked to connect them with providers so that communication felt normal, not exceptional. She understood that when pharmacists are informed and engaged, the entire system functions better.

That kind of leadership does not just influence individual interactions. It shifts expectations across a network.

Treatment Does not Work in Silos

Buprenorphine has changed the landscape of opioid use disorder treatment, but medication alone is not enough. The success of outpatient treatment depends on how well the people involved communicate, coordinate, and respond to what is happening in real time.

When pharmacists are treated as an afterthought, gaps begin to form. Prescriptions are delayed, medications are not in stock, questions go unanswered, and patients are left to navigate those barriers on their own. When pharmacists are included as part of the care team, those same moments become opportunities for intervention, clarification, and support.

I saw this firsthand when I worked with the manufacturers of Suboxone for almost a decade. I would bring providers and pharmacists together in a way that felt intentional. I made sure pharmacists knew who the prescribers were in their community, and providers knew which pharmacies could be relied on. Over time, those relationships became a foundation for better care. People picked up the phone more often. Questions were addressed earlier, and patients experienced fewer delays. This was not complicated work, but it required focus and consistency.

The Reality of Medication Access

There is another side to this that we cannot ignore. Medication access has been a challenge for as long as I have been in this field, and that is now over two decades.

Patients are still walking into pharmacies with valid prescriptions and being told that the medication is not available. Sometimes it is a supply issue. Sometimes it is a business decision. Sometimes it is discomfort or uncertainty on the part of the pharmacist. Regardless of the reason, the impact is the same.

A patient who has taken the step to seek treatment is now faced with another barrier, often at a moment when timing matters most. That kind of disruption can undo progress quickly.

We have made significant advancements in expanding access to buprenorphine, including policy changes that support telehealth prescribing, but access on paper does not always translate to access in practice. If the medication is not on the shelf, the system is not working the way we think it is.

Addressing Stigma Where it Shows Up

Stigma continues to shape how opioid use disorder is treated, and pharmacies are not immune to that reality. Some patients can feel it the moment they approach the counter. There may be hesitation, additional scrutiny, or a shift in tone that communicates something without saying it directly.

This is not just about perception. It affects whether patients feel comfortable returning, whether they ask questions, and whether they stay engaged in treatment. It also affects whether pharmacists feel confident and supported in their role.

Addressing stigma in this space requires more than general awareness. It requires education that is grounded in practice, clear expectations from leadership, and ongoing engagement between pharmacists and the broader care team.

A Missed Opportunity that Can Be Fixed

When I step back and look at the system as a whole, what stands out is how much opportunity exists within the pharmacy setting. Pharmacists are accessible, knowledgeable, and already engaged with patients on a regular basis. They are in a position to reinforce treatment plans, identify early signs of concern, and support continuity of care.

And yet, many outpatient models still treat them as a separate entity rather than an integrated partner.

This is not a structural limitation. It is a design choice.

Organizations that take the time to build relationships with pharmacists, align expectations, and create clear communication pathways tend to see fewer disruptions and stronger engagement. It does not require a complete overhaul of the system, but it does require intention.

Where Vantage Comes In

At Vantage Clinical Consulting, this is exactly the kind of gap we help organizations close. We work with providers to build stronger connections with pharmacists, assess where access breaks down, and create workflows that reflect how care actually happens in the real world.

That includes bringing pharmacists into training conversations, supporting collaborative models between prescribers and dispensers, and addressing the practical and cultural barriers that get in the way of effective treatment.

If outpatient opioid use disorder treatment is going to reach its full potential, pharmacists cannot remain on the sidelines of the strategy. They are already doing the work. The question is whether the system is ready to recognize and support that role in a meaningful way.

#LetTheHealingBegin #OpioidResponse #HealthcareLeadership #MedicationAccess #BehavioralHealth #PharmacyLeadership #VantagePoint